Factors Predictive of Use and of Benefit from Continuous Glucose Monitoring in Type 1 Diabetes

  1. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group (jdrfapp{at}jaeb.org)

    Abstract

    Objective: To evaluate factors associated with successful use of continuous glucose monitoring (CGM) among participants with intensively-treated type 1 diabetes in the JDRF CGM Randomized Clinical Trial.

    Research Design and Methods: The 232 participants randomized to the CGM group (165 with baseline HbA1c ≥7.0% and 67 with HbA1c <7.0%) were asked to use CGM on a daily basis. The associations of baseline factors and early CGM use with CGM use ≥6 days/week in the sixth month and with change in HbA1c from baseline to 6 months were evaluated in regression models.

    Results: The only baseline factors found to be associated with greater CGM use in month 6 were age ≥25 years (P<0.001) and more frequent self-reported pre-study blood glucose meter measurements per day (P<0.001). CGM use and the percentage of CGM glucose values between 71-180 mg/dL during the first month were predictive of CGM use in month 6 (P<0.001 and P=0.002, respectively). More frequent CGM use was associated with a greater reduction in HbA1c from baseline to 6 months (P<0.001), a finding present in all age groups.

    Conclusions: After 6 months, near-daily CGM use is more frequent in intensively-treated adults with type 1 diabetes than in children and adolescents, although in all age groups near-daily CGM use is associated with a similar reduction in HbA1c. Frequency of blood glucose meter monitoring and initial CGM use may help predict the likelihood of long-term CGM benefit in intensively treated patients with type 1 diabetes of all ages.

    Footnotes

      • Received May 14, 2009.
      • Accepted July 21, 2009.

    This Article

    1. Diabetes Care
    1. Online-Only Appendix
    2. All Versions of this Article:
      1. dc09-0889v1
      2. 32/11/1947 most recent